Amneal Pharmaceuticals, Inc.
- Last sale
- Oct 30, 2026 · +0.82%
- Market cap
- $7.49B
- 348.41M shares
- Filings
- 695
Q3 2026+8.0% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+58.1% FY25 yoy
Q3 2026derived+11.0% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+155.1% FY25 yoy
- $7.49B
- 56.2×
- 2.3×
- 14.1×
- 1.18%
- —
Twelve months to Sep 30, 2026 · derived
Price
Oct 30, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $3,018,760,000 | reported | |
| FY 2024 | 2024-12-31 | $2,793,957,000 | reported | |
| FY 2023 | 2023-12-31 | $2,393,607,000 | reported | |
| FY 2022 | 2022-12-31 | $2,212,304,000 | reported | |
| FY 2021 | 2021-12-31 | $2,093,669,000 | reported | |
| FY 2020 | 2020-12-31 | $1,992,523,000 | reported | |
| FY 2019 | 2019-12-31 | $1,626,373,000 | reported | |
| FY 2018 | 2018-12-31 | $1,662,991,000 | reported | |
| FY 2017 | 2017-12-31 | $1,033,654,000 | reported | |
| FY 2016 | 2016-12-31 | $1,018,225,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2020 | $0.00 | — | $0.00 | — | — | — | 0.0% |
| FY2019 | $0.00 | — | $0.00 | — | — | — | — |
| FY2018 | $183.00M | — | $183.00M | — | — | — | 109.5% |
| FY2017 | $375.27M | — | $375.27M | — | 1.00K sh | — | 269.2% |
| FY2016 | $200.62M | $5.00K | $200.62M | — | — | — | — |
Segments
LineFY2025ShareChange
Affordable Medicines$1.75B58%+3.6%
AvKARE$744.73M25%+12.3%
Specialty$528.51M18%+18.6%
Av Kare———
Generics———
Specialty———
Total$3.02B
Pharmaceutical preparations
Amneal Pharmaceuticals, Inc. is the 25th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
JAZZJazz Pharmaceuticals plc$4.3B4.9%8.3%$15.4BPRGOPerrigo Co PLC$4.3B2.8%33.5%$2.2BGMABGenmab A/S$3.7B19.2%25.9%—ALNYAlnylam Pharmaceuticals, Inc.$3.7B65.2%8.4%$21.0BBMRNBioMarin Pharmaceutical Inc$3.2B12.9%10.8%$11.0BUTHRUnited Therapeutics Corp$3.2B10.6%41.9%$25.3B
AMRXAmneal Pharmaceuticals, Inc. (this company)$3.0B8.0%2.4%$7.5B
RPRXRoyalty Pharma plc$2.4B5.1%32.4%$39.6BSRPTSarepta Therapeutics, Inc.$2.2B15.6%32.5%$1.7BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR